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a check-up every 2 months) and it is neither painful (unlike intrale­
sional infiltration with triamcinolone) nor risky [2] (unlike some 
potent topical corticosteroids, which may cause systemic absorption, 
adrenal suppression, and retardation of bone growth). 
This work demonstrates also that any adverse elfect of this therapy 
can be avoided as applications are carried out weekly, with very low 
concentrations, over less than 5% of the body area, in a site, the head, 
which is quite tolerant to topical allergens. Because irritation is not a 
prerequisite of recovery, we believe that SADBE is a suitable treatment 
even for children resistant to other therapies [3-5]. 
Therefore, considering the advantages due to its easy application 
and to the absence of side elfects, we attest to the validity of SAD BE 
as a suitable treatment particularly apt in children resistant to 
conventional therapies. 
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T opical diphenylcyclopropenone and rninoxidil have been used in the treatment of alopecia areata with variable results [1-5]. This study was designed to evaluate the efficacy of diphenylcyclopropenone alone or in combination 
with topical 5% minoxidil for the treatment of chronic severe 
alopecia areata. The elfect of therapy on cutuaneous T-cell and 
Langerhans cell subpopulations and intercellular adhesions mole­
cule-1 expression was also examined. 
Fifteen patients with chronic (more than 2 years), severe (more 
than 50% scalp involvement) alopecia areata participated in a 
24-week trial. Half of the scalp was treated with diphenylcyclopro­
penone once weekly and with either 5% rninoxidil solution or a 
vehicle solution twice daily in a randomized double-blind design. 
Skin biopsy specimens from each half of the scalp were obtained 
before therapy and after 12 and 24 weeks of therapy for histologic 
immunophenotypic analysis. 
Thirteen patients completed the study. Five of the 13 patients 
(38%) showed marked regrowth of coarse terminal hair after 24 
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weeks of treatment with DPCP. The addition of topical 5% 
rninoxidil did not produce any significant clinical benefit in this 
24-week trial. Immunophenotypic analysis showed no differ­
ences between responders and nonresponders at baseline. 
During treatment, Leu-4, Leu-2, and Leu-3 and keratinocyte 
intercellular adhesion molecule 1 expression were signifi­
cantly reduced in biopsy specimens of responders versus non­
responders. 
Diphenylcyclopropenone treatment showed a 38% success rate in 
producing cosmetically acceptable regrowth in patients with 
chronic severe alopecia. 
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